The Europe Clot Busting Drugs Market should witness market growth of 7.7% CAGR during the forecast period (2023-2030).
Plans for treatment and the optimum usage of clot-buster therapy can be created using genetic testing, biomarker analysis, and the unique characteristics of each patient. Targeted therapies are made possible by personalized medicine approaches, improving treatment outcomes and patient satisfaction. Therefore, stroke is a severe public health issue with significant economic and social repercussions. These are the main variables anticipated to generate growth possibilities for market participants during the projected period.
Clot busting drugs can help by dissolving blood clots collecting in the veins, which lowers blood pressure, and can help with the increased incidence of strokes. The market is growing due to strokes expanding the population's mortality rate. Additionally, it is predicted that the market will grow throughout the projection period due to the rising risk of ischemic stroke in the population. A considerable death rate is associated with stroke and significant morbidity, which leaves up to 50% of survivors with a long-term disability. As a result, stroke is a disorder crucial to public health and significantly negatively affects the economy and society.
In the UK, combating obesity is one of the nation’s major long-term health issues. Nowadays, over two-thirds (63%) of people are overweight, and approximately half are obese. One-third of children leaving primary school are overweight or obese, and one-fifth of youngsters are obese. The high prevalence of obesity and its associated health issues are anticipated to increase the risk of health conditions such as CVD and others. As a result, the rising obesity across the regional nations further raise the need for the clot busting drugs, hence supporting the regional market expansion.
The Germany market dominated the Europe Clot Busting Drugs Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $3.1 billion by 2030. The UK market is poised to grow at a CAGR of 6.8% during (2023-2030). Additionally, The France market should witness a CAGR of 8.5% during (2023-2030).
Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Online Pharmacy. Based on Product, the market is segmented into Anticoagulants, Thrombolytic Drugs, Anti-Platelet Drugs and Others. Based on Route of Administration, the market is segmented into Injectable and Oral. Based on Indication, the market is segmented into Pulmonary Embolism, Atrial Fibrillation, Deep Vein Thrombosis and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Sanofi S.A., Dr. Reddy’s Laboratories Ltd., Bayer AG, Boehringer Ingelheim International GmbH, Sun Pharmaceutical Industries Ltd., Bristol Myers Squibb Company, Eli Lilly And Company, Johnson & Johnson (Johnson & Johnson Services, Inc.), Pfizer, Inc., Merck & Co., Inc.
Plans for treatment and the optimum usage of clot-buster therapy can be created using genetic testing, biomarker analysis, and the unique characteristics of each patient. Targeted therapies are made possible by personalized medicine approaches, improving treatment outcomes and patient satisfaction. Therefore, stroke is a severe public health issue with significant economic and social repercussions. These are the main variables anticipated to generate growth possibilities for market participants during the projected period.
Clot busting drugs can help by dissolving blood clots collecting in the veins, which lowers blood pressure, and can help with the increased incidence of strokes. The market is growing due to strokes expanding the population's mortality rate. Additionally, it is predicted that the market will grow throughout the projection period due to the rising risk of ischemic stroke in the population. A considerable death rate is associated with stroke and significant morbidity, which leaves up to 50% of survivors with a long-term disability. As a result, stroke is a disorder crucial to public health and significantly negatively affects the economy and society.
In the UK, combating obesity is one of the nation’s major long-term health issues. Nowadays, over two-thirds (63%) of people are overweight, and approximately half are obese. One-third of children leaving primary school are overweight or obese, and one-fifth of youngsters are obese. The high prevalence of obesity and its associated health issues are anticipated to increase the risk of health conditions such as CVD and others. As a result, the rising obesity across the regional nations further raise the need for the clot busting drugs, hence supporting the regional market expansion.
The Germany market dominated the Europe Clot Busting Drugs Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $3.1 billion by 2030. The UK market is poised to grow at a CAGR of 6.8% during (2023-2030). Additionally, The France market should witness a CAGR of 8.5% during (2023-2030).
Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Online Pharmacy. Based on Product, the market is segmented into Anticoagulants, Thrombolytic Drugs, Anti-Platelet Drugs and Others. Based on Route of Administration, the market is segmented into Injectable and Oral. Based on Indication, the market is segmented into Pulmonary Embolism, Atrial Fibrillation, Deep Vein Thrombosis and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Sanofi S.A., Dr. Reddy’s Laboratories Ltd., Bayer AG, Boehringer Ingelheim International GmbH, Sun Pharmaceutical Industries Ltd., Bristol Myers Squibb Company, Eli Lilly And Company, Johnson & Johnson (Johnson & Johnson Services, Inc.), Pfizer, Inc., Merck & Co., Inc.
Scope of the Study
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
By Product
- Anticoagulants
- Thrombolytic Drugs
- Anti-Platelet Drugs
- Others
By Route of Administration
- Injectable
- Oral
By Indication
- Pulmonary Embolism
- Atrial Fibrillation
- Deep Vein Thrombosis
- Others
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- Sanofi S.A.
- Dr. Reddy’s Laboratories Ltd.
- Bayer AG
- Boehringer Ingelheim International GmbH
- Sun Pharmaceutical Industries Ltd.
- Bristol Myers Squibb Company
- Eli Lilly And Company
- Johnson & Johnson (Johnson & Johnson Services, Inc.)
- Pfizer, Inc.
- Merck & Co., Inc.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. Europe Clot Busting Drugs Market by Distribution Channel
Chapter 5. Europe Clot Busting Drugs Market by Product
Chapter 6. Europe Clot Busting Drugs Market by Route of Administration
Chapter 7. Europe Clot Busting Drugs Market by Indication
Chapter 8. Europe Clot Busting Drugs Market by Country
Chapter 9. Company Profiles
Companies Mentioned
- Sanofi S.A.
- Dr. Reddy’s Laboratories Ltd.
- Bayer AG
- Boehringer Ingelheim International GmbH
- Sun Pharmaceutical Industries Ltd.
- Bristol Myers Squibb Company
- Eli Lilly And Company
- Johnson & Johnson (Johnson & Johnson Services, Inc.)
- Pfizer, Inc.
- Merck & Co., Inc.
Methodology
LOADING...
